Guggenheim lowered the firm’s price target on Regeneron (REGN) to $950 from $1,200 and keeps a Buy rating on the shares. The firm, which is ...
Regeneron (REGN) announced that the U.S. Food and Drug Administration has accepted for review the resubmission of the Biologics License ...
This was the stock's second consecutive day of losses.
The stock's fall snapped a three-day winning streak.
Veru's experimental drug helps older obese patients on Wegovy preserve muscle January 27, 2025 Medical data research company Truveta said on Monday that Regeneron Pharmaceuticals , Illumina and 17 ...
Want to brand your business without breaking the bank? The best free logo maker will be an essential tool in your marketing kit - and after testing these completely free logo designers ...
It's a web-based service that can auto-generate logos. All you need to do is add your company's name, as well as provide information on what sort of business you offer, as well as picking a few ...
Then, on October 31, 2024, Regeneron announced financial results for Q3 2024 that included disappointing U.S. net sales for its EYLEA and EYLEA HD products. The company revealed that those sales ...
SAN FRANCISCO — Just over 20 years ago, the people of California voted to spend billions of dollars on an exciting new idea to remake medicine … ...
Inc. ("Regeneron" or the "Company") (NASDAQ: REGN) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Regeneron investors who were adversely ...
Regeneron is a leading biotechnology company that was founded and is led by physician-scientists to translate science into medicines. This has led to the development of numerous approved ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback
